The CDC advisory panel is set to
meet this Friday to discuss the next steps for Johnson & Johnson's (NYSE:
JNJ) COVID-19 vaccine, and Dr. Anthony Fauci wouldn't be surprised if there is a decision that would resume vaccinations. "My estimate is that we will continue to use it in some form. I doubt very seriously if they just cancel it. I don't think that's going to happen. I do think that there will likely be some sort of warning or restriction or risk assessment," he told NBC's
Meet the Press. Meanwhile, in a letter published in
The New England Journal of Medicine just before the weekend, three J&J scientists said there wasn't enough evidence to support a link between its vaccine and blood clots.
Backdrop: Last Tuesday, U.S. health regulators
recommended that the use of the J&J's inoculation be paused "out of an abundance of caution" following reports of six cases of rare brain blood clots in women aged between 18 to 48 (one even died and another is in critical condition). That's out of some 7.8M people who have received the jab across United States. JNJ's single-dose shot was developed using an adenovirus vector similar to AstraZeneca's (NASDAQ:
AZN) two-dose vaccine, which has also led to blood clot concerns in Europe.
Later in the week, White House COVID-19 Response Coordinator Jeff Zients said the Johnson and Johnson halt would
not have a significant impact on the overall U.S. vaccination program. "We have more than enough supply of Pfizer and Moderna vaccines to continue the current pace of about 3M shots per day," he told reporters at a press briefing. The country is averaging 3.3M daily vaccine doses administered over the past week, and 3M when counting only Pfizer (NYSE:
PFE) and Moderna (NASDAQ:
MRNA).
Was it the right decision? Critics point to the fact that COVID-19 has killed 566,000 Americans, while blood clots from the vaccines have resulted in one death. There are also concerns about vaccine credibility, especially among populations that have so far been hesitant to take it, while some suggest that regulators should have just stopped giving the J&J jab to younger women, who appear to be most at risk of developing the rare blood clots. However, given the fact that the U.S. vaccination can continue at 3M shots per day even without J&J, others are supporting the suspension until more data is available.